FIBROBLAST GROWTH FACTOR-21-Fc FUSION PROTEINS
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/539,280, filed Sep 26, 2011. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,006,400 | FIBROBLAST GROWTH FACTOR-21-Fc FUSION PROTEINS In force · High confidence | Novartis AG | In force | High confidence | ||
| US 9,266,935 | Methods of Treating Metabolic Disorders with an FGF21 Variant In force · High confidence | Novartis AG | In force | High confidence | ||
| US 10,076,554 | FGF21-FC Fusion Proteins for Treating Metabolic Disorders In force · High confidence | Novartis AG | In force | High confidence | ||
| US 11,129,874 | NUCLEIC ACIDS ENCODING FGF21-Fc FUSION PROTEINS In force · High confidence | Novartis AG | In force | High confidence | ||
| US 11,944,664 | Fibroblast Growth Factor-21-Fc Fusion Proteins In force · High confidence | Novartis AG | In force | High confidence | ||
| US 12,527,841 | Fibroblast Growth FACTOR-21-FC Fusion Proteins In force · High confidence | Novartis AG | In force | High confidence | ||
| Application 19/426,572 | Fibroblast Growth FACTOR-21-FC Fusion Proteins Pending Not granted | Novartis AG | Pending | Not granted |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Novartis AG.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.